69 related articles for article (PubMed ID: 2476630)
41. Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs.
Fryer RM; Rakestraw PA; Preusser LC; Brune ME; Carroll WA; Buckner SA; Shieh CC; King LL; Marsh KC; Gopalakrishnan M; Cox BF; Reinhart GA
J Cardiovasc Pharmacol; 2005 Aug; 46(2):232-40. PubMed ID: 16044036
[TBL] [Abstract][Full Text] [Related]
42. In vitro effects of the new calcium antagonist lacidipine.
Kawada T; Sun HT; Nakazawa M; Imai S
Jpn J Pharmacol; 1993 Jul; 62(3):289-96. PubMed ID: 8411776
[TBL] [Abstract][Full Text] [Related]
43. Active conformation of 1,4-dihydropyridine calcium entry blockers. Effect of size of 2-aryl substituent on rotameric equilibria and receptor binding.
Rovnyak G; Andersen N; Gougoutas J; Hedberg A; Kimball SD; Malley M; Moreland S; Porubcan M; Pudzianowski A
J Med Chem; 1991 Aug; 34(8):2521-4. PubMed ID: 1652021
[TBL] [Abstract][Full Text] [Related]
44. Cardiovascular profile of the new dihydropyridine derivative S12968.
Sassen LM; Van der Zande J; McFalls EO; Verdouw PD
Eur J Pharmacol; 1991 Jun; 199(1):61-7. PubMed ID: 1893928
[TBL] [Abstract][Full Text] [Related]
45. Activity of dihydrothienopyridine S312 enantiomers on L-type Ca2+ channels in isolated rat aorta and cerebral microvessels.
Dessy C; Salomone S; Morel N; Godfraind T
Eur J Pharmacol; 1993 Feb; 231(3):435-42. PubMed ID: 8449235
[TBL] [Abstract][Full Text] [Related]
46. [Effects of pranidipine (OPC-13340), a novel 1,4-dihydropyridine derivative Ca-antagonist, on isolated porcine coronary contraction and acute myocardial ischemia in the pig].
Ohura M; Mori T; Watanabe K; Ikezono K; Nakayama N; Tominaga M; Yabuuchi Y
Nihon Yakurigaku Zasshi; 1994 Mar; 103(3):101-9. PubMed ID: 8144102
[TBL] [Abstract][Full Text] [Related]
47. Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart.
Jeppesen P; Bruun J; Nielsen-Kudsk F
Pharmacol Toxicol; 1998 May; 82(5):250-6. PubMed ID: 9646331
[TBL] [Abstract][Full Text] [Related]
48. [2-Aryl substituted benzo-anellated 5-ring-heterocycles as potential agents for the cardiovascular system. 2. 1,3-Benzimidazoles].
Rose U
Pharmazie; 1991 Nov; 46(11):775-7. PubMed ID: 1811227
[TBL] [Abstract][Full Text] [Related]
49. Calcium antagonists and left ventricular function: effects of nitrendipine in congestive heart failure.
Cohn JN
Am J Cardiol; 1986 Sep; 58(8):27D-30D. PubMed ID: 2876622
[TBL] [Abstract][Full Text] [Related]
50. Novel halogenated dihydropyridine derivatives with high vascular selectivity.
Fricke U; Klaus W; Stein B
Naunyn Schmiedebergs Arch Pharmacol; 1988 Oct; 338(4):449-54. PubMed ID: 3244387
[TBL] [Abstract][Full Text] [Related]
51. The influence of 3-ester side chain variation on the cardiovascular profile of nitrendipine in porcine isolated trabeculae and coronary arteries.
Kojda G; Klaus W; Werner G; Fricke U
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):488-94. PubMed ID: 1766474
[TBL] [Abstract][Full Text] [Related]
52. High and concentration-proportional accumulation of [3H]-nitrendipine by intact cardiac tissue.
Lüllmann H; Mohr K
Br J Pharmacol; 1987 Mar; 90(3):567-74. PubMed ID: 3567462
[TBL] [Abstract][Full Text] [Related]
53. 2(1H)-quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives.
Alabaster CT; Bell AS; Campbell SF; Ellis P; Henderson CG; Roberts DA; Ruddock KS; Samuels GM; Stefaniak MH
J Med Chem; 1988 Oct; 31(10):2048-56. PubMed ID: 2845085
[TBL] [Abstract][Full Text] [Related]
54. LY249933: a cardioselective 1,4-dihydropyridine with positive inotropic activity.
Holland DR; Wikel JH; Kauffman RF; Smallwood JK; Zimmerman KM; Utterback BG; Turk JA; Steinberg MI
J Cardiovasc Pharmacol; 1989 Sep; 14(3):483-91. PubMed ID: 2476630
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
56. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604
[TBL] [Abstract][Full Text] [Related]
57. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding.
Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181
[TBL] [Abstract][Full Text] [Related]
58. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.
Millard RW; Grupp G; Grupp IL; DiSalvo J; DePover A; Schwartz A
Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652
[TBL] [Abstract][Full Text] [Related]
59. PY 108-068: a calcium antagonist with an unusual pattern of cardiovascular activity.
Hof RP
Gen Pharmacol; 1985; 16(1):1-6. PubMed ID: 2579873
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
